| |
| |
|
| Insider
Information: |
Vaishnaw Akshay |
| Relationship: |
President |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
22,774 |
|
|
Indirect Shares
|
515 |
|
|
| Direct
Value |
$3,400,158 |
|
|
|
Indirect Value
|
$76,890 |
|
|
| Total
Shares |
23,289 |
|
|
| Total
Value |
$3,477,048 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -26.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alnylam Pharmaceuticals Inc |
ALNY |
President |
2023-08-04 |
22,774 |
2023-08-04 |
515 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2018-03-14 |
4 |
AS |
$140.45 |
$12,672,126 |
D/D |
(88,554) |
11,215 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2018-03-14 |
4 |
OE |
$7.10 |
$1,507,842 |
D/D |
88,554 |
99,769 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
SVP, R&D |
• – – |
2017-05-15 |
4 |
OE |
$21.35 |
$1,262,873 |
D/D |
43,750 |
21,297 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
SVP, R&D |
• – – |
2017-05-15 |
4 |
AS |
$65.00 |
$2,843,750 |
D/D |
(43,750) |
10,297 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2023-02-10 |
4 |
AS |
$213.13 |
$8,216,324 |
D/D |
(38,044) |
14,970 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
SVP, Chief Medical Officer |
• – – |
2012-07-16 |
4 |
OE |
$9.14 |
$335,325 |
D/D |
36,250 |
23,838 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
SVP, Chief Medical Officer |
• – – |
2012-07-16 |
4 |
AS |
$19.00 |
$688,750 |
D/D |
(36,250) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
• – – |
2017-10-30 |
4 |
OE |
$21.35 |
$718,769 |
D/D |
33,666 |
45,201 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
• – – |
2017-10-30 |
4 |
AS |
$119.79 |
$4,088,967 |
D/D |
(33,666) |
11,535 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2014-03-18 |
4 |
OE |
$7.10 |
$380,002 |
D/D |
32,769 |
32,769 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2014-03-18 |
4 |
AS |
$73.34 |
$2,423,223 |
D/D |
(32,769) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2023-02-10 |
4 |
OE |
$63.00 |
$1,947,519 |
D/D |
30,913 |
53,014 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D, CMO |
• – – |
2016-11-30 |
4 |
OE |
$22.75 |
$663,504 |
D/D |
29,165 |
34,915 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D, CMO |
• – – |
2016-11-30 |
4 |
AS |
$44.34 |
$1,311,998 |
D/D |
(29,165) |
5,750 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2020-02-07 |
4 |
AS |
$125.00 |
$2,963,500 |
D/D |
(23,708) |
11,215 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2020-02-07 |
4 |
OE |
$42.22 |
$960,505 |
D/D |
22,750 |
34,923 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2020-04-20 |
4 |
OE |
$42.22 |
$927,616 |
D/D |
21,971 |
36,090 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2020-04-20 |
4 |
AS |
$140.00 |
$3,075,940 |
D/D |
(21,971) |
14,119 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-12-17 |
4 |
AS |
$60.59 |
$1,127,761 |
D/D |
(18,480) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-12-17 |
4 |
OE |
$12.96 |
$239,501 |
D/D |
18,480 |
31,068 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-06-11 |
4 |
OE |
$7.10 |
$127,900 |
D/D |
15,000 |
17,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-06-11 |
4 |
AS |
$31.07 |
$466,137 |
D/D |
(15,000) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-12-16 |
4 |
OE |
$7.10 |
$127,900 |
D/D |
15,000 |
27,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-12-16 |
4 |
AS |
$60.19 |
$905,298 |
D/D |
(15,000) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2021-06-18 |
4 |
AS |
$175.00 |
$2,573,900 |
D/D |
(14,708) |
11,215 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
